MCID: LTT002
MIFTS: 54

Letterer-Siwe Disease malady

Categories: Genetic diseases, Rare diseases, Respiratory diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Letterer-Siwe Disease

About this section
Sources:
11Disease Ontology, 13DISEASES, 25Genetics Home Reference, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Letterer-Siwe Disease:

Name: Letterer-Siwe Disease 52 11 54 68
Histiocytosis X 11 48 25 50
Langerhans Cell Histiocytosis 48 25 50
Histiocytosis, Langerhans-Cell 39 68
Langerhans Cell Granulomatosis 11 25
Langerhans-Cell Histiocytosis 11 13
Hashimoto-Pritzger Disease 25 68
Lch 48 25
Letterer-Siwe Disease Involving Lymph Nodes of Inguinal Region and Lower Limb 11
Letterer-Siwe Disease of Lymph Nodes of Inguinal Region Amd/or Lower Limb 11
Letterer-Siwe Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 11
Letterer-Siwe Disease of Lymph Nodes of Inguinal Region and Lower Limb 11
Letterer-Siwe Disease Involving Lymph Nodes of Axilla and Upper Limb 11
Letterer-Siwe Disease Involving Lymph Nodes of Head, Face, and Neck 11
Letterer-Siwe Disease Involving Lymph Nodes of Head, Face and Neck 11
Letterer-Siwe Disease of Lymph Nodes of Axilla and/or Upper Limb 11
 
Letterer-Siwe Disease of Lymph Nodes of Head, Face and/or Neck 11
Letterer-Siwe Disease of Lymph Nodes of Axilla and Upper Limb 11
Letterer-Siwe Disease Involving Lymph Nodes of Multiple Sites 11
Letterer-Siwe Disease of Lymph Nodes of Head, Face and Neck 11
Letterer-Siwe Disease Involving Intra-Abdominal Lymph Nodes 11
Letterer-Siwe Disease Involving Intrathoracic Lymph Nodes 11
Letterer-Siwe Disease Involving Intrapelvic Lymph Nodes 11
Letterer-Siwe Disease of Lymph Nodes of Multiple Sites 11
Letterer-Siwe Disease of Intra-Abdominal Lymph Nodes 11
Acute and Disseminated Langerhans Cell Histiocytosis 54
Letterer-Siwe Disease of Intrathoracic Lymph Nodes 11
Letterer-Siwe Disease of Intrapelvic Lymph Nodes 11
Letterer-Siwe Disease Involving Spleen 11
Letterer-Siwe Disease of Spleen 11
Langerhan's Cell Histiocytosis 11
Familial Letterer-Siwe Disease 39

Characteristics:

Orphanet epidemiological data:

54
letterer-siwe disease:
Prevalence: 1-9/1000000 (Europe); Age of onset: Infancy,Neonatal

HPO:

64
letterer-siwe disease:
Inheritance: autosomal recessive inheritance

Classifications:



External Ids:

OMIM52 246400
Disease Ontology11 DOID:2571
ICD9CM32 202.5
Orphanet54 ORPHA99870
ICD10 via Orphanet31 C96.0
MESH via Orphanet40 C538636
UMLS via Orphanet69 C0023381

Summaries for Letterer-Siwe Disease

About this section
NIH Rare Diseases:48 Langerhans cell histiocytosis (LCH) is a disorder that primarily affects children, but is also found in adults of all ages. People with LCH produce too many Langerhans cells or histiocytes, a form of white blood cell found in healthy people that is supposed to protect the body from infection. In people with LCH, these cells multiply excessively and build up in certain areas of the body, causing tumors called granulomas to form. The symptoms vary among affected individuals, and the cause of LCH is unknown. In most cases, this condition is not life-threatening. Some people do experience life-long problems associated with LCH. Last updated: 10/18/2013

MalaCards based summary: Letterer-Siwe Disease, also known as histiocytosis x, is related to adult pulmonary langerhans cell histiocytosis and non-langerhans-cell histiocytosis, and has symptoms including irritability, abnormality of the skeletal system and jaundice. An important gene associated with Letterer-Siwe Disease is CD207 (CD207 Molecule), and among its related pathways are G-protein signaling TC21 regulation pathway and Trk receptor signaling mediated by the MAPK pathway. The drug thalidomide has been mentioned in the context of this disorder. Affiliated tissues include lymph node, spleen and bone, and related mouse phenotypes are integument and homeostasis/metabolism.

Disease Ontology:11 A histiocytosis that is characterized by clonal proliferation of Langerhans cells.

Genetics Home Reference:25 Langerhans cell histiocytosis is a disorder in which excess immune system cells called Langerhans cells build up in the body. Langerhans cells, which help regulate the immune system, are normally found throughout the body, especially in the skin, lymph nodes, spleen, lungs, liver, and bone marrow. In Langerhans cell histiocytosis, excess immature Langerhans cells usually form tumors called granulomas. However, Langerhans cell histiocytosis is not generally considered to be a form of cancer.

Description from OMIM:52 246400

Related Diseases for Letterer-Siwe Disease

About this section

Diseases related to Letterer-Siwe Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 54)
idRelated DiseaseScoreTop Affiliating Genes
1adult pulmonary langerhans cell histiocytosis12.5
2non-langerhans-cell histiocytosis12.4
3lissencephaly with cerebellar hypoplasia11.7
4leydig cell hypoplasia11.4
5leydig cell hypoplasia with pseudohermaphroditism10.8
6lissencephaly 210.8
7progressive nodular histiocytosis10.5F13A1, S100B
8diffuse pulmonary fibrosis10.5LYZ, S100B
9soft tissue peripheral neuroepithelioma10.4CD1A, F13A1
10prostate stromal sarcoma10.4CD1A, CD207
11myopia10.4CSF1, F13A1
12histiocytosis10.4
13skull base meningioma10.4CD163, CD207
14eosinophilic granuloma10.4
15eosinophilic granulomatosis with polyangiitis10.3CD1A, CD207, F13A1
16dens in dente and palatal invaginations10.3CD1A, CD207, S100B
17dendritic cell thymoma10.3AVP, S100B
18pancreatic intraductal papillary-mucinous adenoma10.3CD163, LYZ
19luteoma10.3CD163, LYZ
20pulmonary venoocclusive disease10.3BRAF, S100B
21malignant adenofibroma10.2F13A1, LYZ, S100B
22mucinoses10.2CD163, CSF1
23non-congenital cyst of kidney10.2F13A1, S100B
24hyperpituitarism10.2CD163, LYZ
25epithelioid cell melanoma10.2BRAF, S100B
26epicardium cancer10.2BRAF, S100B
27adenosquamous bile duct carcinoma10.1CD163, CD207, LYZ
28neutrophil immunodeficiency syndrome10.1CD163, F13A1, S100B
29sporadic idiopathic steroid-resistant nephrotic syndrome with minimal changes10.1CD163, CSF1, S100B
30benign breast adenomyoepithelioma10.1CD163, CD207
31pancreatic delta cell neoplasm10.1CD163, F13A1, LYZ
32parovarian cyst10.1CD163, F13A1, LYZ
33spondylohypoplasia, arthrogryposis and popliteal pterygium10.0CD163, CD40, CSF1
34gallbladder leiomyosarcoma10.0CD163, S100B
35sterility due to immotile flagella10.0CSF1, LIF
36leukemia10.0
37pneumonia10.0
38radioulnar synostosis10.0BRAF, MAP2K1
39epidural neoplasm9.9F13A1, LYZ
40protein-losing enteropathy9.8
41pneumocystosis9.8
42choroiditis9.8
43diarrhea9.8
44obstructive jaundice9.8
45splenic infarction9.8
46retinitis9.8
47retinal degeneration9.8
48monocytic leukemia9.8
49malignant histiocytosis9.8
50subacute monocytic leukemia9.8

Graphical network of the top 20 diseases related to Letterer-Siwe Disease:



Diseases related to letterer-siwe disease

Symptoms & Phenotypes for Letterer-Siwe Disease

About this section

Symptoms by clinical synopsis from OMIM:

246400

Clinical features from OMIM:

246400

Human phenotypes related to Letterer-Siwe Disease:

 64 (show all 15)
id Description HPO Frequency HPO Source Accession
1 irritability64 HP:0000737
2 abnormality of the skeletal system64 HP:0000924
3 jaundice64 HP:0000952
4 pallor64 HP:0000980
5 seborrheic dermatitis64 HP:0001051
6 encephalopathy64 HP:0001298
7 hepatosplenomegaly64 HP:0001433
8 thrombocytopenia64 HP:0001873
9 neutropenia64 HP:0001875
10 anemia64 HP:0001903
11 fever64 HP:0001945
12 dyspnea64 HP:0002094
13 pulmonary infiltrates64 HP:0002113
14 abdominal distention64 HP:0003270
15 stomatitis64 HP:0010280

UMLS symptoms related to Letterer-Siwe Disease:


hepatomegaly

MGI Mouse Phenotypes related to Letterer-Siwe Disease according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00107717.9BRAF, CSF1, LIF, LYZ, MAP2K1, OAT
2MP:00053766.8AVP, BRAF, CD40, CSF1, F13A1, LIF
3MP:00036316.5AVP, BRAF, CD40, CSF1, LIF, LYZ

Drugs & Therapeutics for Letterer-Siwe Disease

About this section

Drugs for Letterer-Siwe Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 110)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Prednisoloneapproved, vet_approvedPhase 2, Phase 3, Phase 1115350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
2
Busulfanapproved, investigationalPhase 2, Phase 3, Phase 154055-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
3
Methylprednisoloneapproved, vet_approvedPhase 2, Phase 3, Phase 1115383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
4
Cyclophosphamideapproved, investigationalPhase 2, Phase 3, Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
5
Prednisoneapproved, vet_approvedPhase 3, Phase 2135953-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
6
MethotrexateapprovedPhase 3, Phase 215181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
7
leucovorinapprovedPhase 3, Phase 2108958-05-9143, 54575
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
8
VinblastineapprovedPhase 3, Phase 2413865-21-413342, 241903
Synonyms:
(2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE
(2alpha,2'BETA,3beta,4alpha,5beta)-vincaleukoblastine
(2xi,3beta,4'beta,19xi)-vincaleukoblastine
(3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino(8,1-cd)carbazole-5-carboxylate
143-67-9
1z2b
29060-LE
865-21-4
AC-20335
AC1L21JC
AC1L68D2
AC1MXZJ2
BIDD:PXR0201
BRD-K01188359-065-02-5
BSPBio_001228
BSPBio_003594
Bio-0111
C07201
C46H58N4O9
CCRIS 9002
CHEBI:171516
CHEBI:27375
CHEMBL159
CHEMBL607706
CID13342
CID241903
CID3823887
CID6710780
D08675
DB00570
EINECS 212-734-0
HMS2090K05
HSDB 3263
KBio3_003033
LS-1859
LS-187263
 
MolPort-002-518-262
MolPort-005-910-359
NCGC00022585-04
NCGC00181127-01
NCI-C04842
NCI60_004200
NChemBio.2007.10-comp22
NDC 0002-1452-01
NSC 47842
Neuro_000020
Nincaluicolflastine
Rozevin
SPBio_000680
STOCK1N-38480
Spectrum2_000890
Spectrum3_001994
UNII-5V9KLZ54CY
VLB
VR-8
Velban
Velbe
Vinblastin
Vinblastina
Vinblastina (TN)
Vinblastina [DCIT]
Vinblastina [Dcit]
Vinblastine
Vinblastine (INN)
Vinblastine Sulfate
Vinblastine [INN:BAN]
Vinblastinum
Vinblastinum [INN-Latin]
Vincaleucoblastin
Vincaleucoblastine
Vincaleukoblastine
Vincoblastine
nchembio873-comp22
vinblastine
9
Indomethacinapproved, investigationalPhase 2, Phase 311453-86-13715
Synonyms:
1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid
1z9h
37242-43-6
503560-73-4
53-86-1
74252-25-8 (hydrochloride salt, tri-hydrate)
7681-54-1 (hydrochloride salt)
91853-74-6
AB00052022
AC-532
AC1L1GJQ
AKOS000592893
Aconip
Aconip (TN)
Amuno
Apo-Indomethacin
Arthrexin
Artracin
Artrinovo
Artrivia
BIDD:GT0132
BIM-0050670.0001
BPBio1_000160
BRD-K57222227-001-06-1
BRN 0497341
BSPBio_000144
BSPBio_001149
BSPBio_002176
Bio-0704
Bio2_000405
Bio2_000885
Bonidin
Bonidon
Bonidon Gel
C01926
CAS-53-86-1
CCRIS 3502
CHEBI:49662
CHEMBL6
CID3715
CPD-10545
Catlep
Chibro-amuno
Chrono-indicid
Chrono-indocid
Confortid
D00141
DB00328
DESMETHYL INDOMETHACIN
DivK1c_000271
Dolcidium
Dolcidium PL
Dolovin
Durametacin
EINECS 200-186-5
EU-0100692
Elmetacin
Flexin continus
HMS1362I11
HMS1568H06
HMS1792I11
HMS1920F21
HMS1990I11
HMS2089N19
HMS2091N09
HMS500N13
HSDB 3101
Hicin
I 7378
I0655
I7378_SIGMA
I8280_SIGMA
IDI1_000271
IDI1_002160
IMN
IN1454
Idomethine
Imbrilon
Inacid
Indacin
Indameth
Indmethacine
Indo-Lemmon
Indo-Spray
Indo-phlogont
Indo-rectolmin
Indo-tablinen
Indocid
Indocid (pharmaceutical)
Indocid Pda
Indocid Sr
Indocin
Indocin (TN)
Indocin I.V
Indocin I.V.
Indocin Sr
Indolar SR
Indomecol
Indomed
Indomee
Indomet 140
Indometacin
Indometacin (JP15/INN)
Indometacina
Indometacina [INN-Spanish]
Indometacine
Indometacine [INN-French]
Indometacinum
 
Indometacinum [INN-Latin]
Indometacyna
Indometacyna [Polish]
Indomethacin
Indomethacin & MAP-30
Indomethacin (USP)
Indomethacin [USAN:BAN]
Indomethacin, Indochron E-R, Indocin-SR, Indocid, Indocin, Indomethacin
Indomethacine
Indomethacinum
Indomethancin
Indomethazine
Indomethegan
Indomethine
Indometicina
Indometicina [Spanish]
Indomo
Indomod
Indoptic
Indoptol
Indorektal
Indoxen
Inflazon
Infrocin
Inteban sp
KBio1_000271
KBio2_000489
KBio2_001399
KBio2_003057
KBio2_003967
KBio2_005625
KBio2_006535
KBio3_000897
KBio3_000898
KBio3_001396
KBioGR_000395
KBioGR_000489
KBioSS_000489
KBioSS_001399
L000959
LS-187
LS-82147
Lausit
Liometacen
Lopac-I-7378
Lopac0_000692
MLS000069402
MLS000758212
MLS001074194
Metacen
Metartril
Methazine
Metindol
Mezolin
Miametan
Mikametan
Mobilan
MolMap_000032
MolPort-000-917-894
NCGC00015562-01
NCGC00015562-02
NCGC00015562-03
NCGC00015562-08
NCGC00015562-19
NCGC00024135-02
NCGC00024135-04
NCGC00024135-05
NCGC00024135-06
NCGC00024135-07
NCGC00024135-08
NCGC00024135-09
NCGC00024135-11
NCI-C56144
NCI60_041708
NINDS_000271
Novo-Methacin
Novomethacin
Oprea1_686105
Prestwick0_000272
Prestwick1_000272
Prestwick2_000272
Prestwick3_000272
Prestwick_597
Reumacide
Rhemacin LA
Rheumacin LA
S00108
S1723_Selleck
SMR000058195
SMR000449290
SPBio_000979
SPBio_002363
SPECTRUM1500350
Sadoreum
Spectrum2_000970
Spectrum3_000468
Spectrum4_000018
Spectrum5_000868
Spectrum_000919
Tannex
Tocris-1708
UNII-XXE1CET956
UPCMLD-DP023
UPCMLD-DP023:001
USAN
Vonum
indometacin
indomethacin
nchembio.147-comp11
{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid
10
Vincristineapproved, investigationalPhase 2, Phase 39042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
11
Cytarabineapproved, investigationalPhase 2, Phase 31093147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
12
Cladribineapproved, investigationalPhase 2, Phase 3714291-63-820279
Synonyms:
(2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
2 Chlorodeoxyadenosine
2'-Deoxy-2-chloroadenosine
2-CdA
2-Chloro-2'-deoxy-beta-adenosine
2-Chloro-2'-deoxyadenosine
2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine
2-Chlorodeoxyadenosine
2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine
2-chloro-Deoxyadenosine
2-chloro-deoxyadenosine
24757-90-2
2CdA
2ClAdo
4291-63-8
AC-7591
AC1L2FXP
Adenosine, 2-chloro-2'-deoxy
BRN 0624220
C10H12ClN5O3.C3H8
CHEBI:567361
CHEMBL1619
CID20279
CL9
CPD000058553
Chlorodeoxyadenosine
Cladarabine
Cladaribine
Cladribina
Cladribine
Cladribine (JAN/USAN/INN)
Cladribine [USAN:INN:BAN]
Cladribinum
 
CldAdo
D01370
D017338
DB00242
FT-0080707
HMS2052K13
HSDB 7564
LS-15109
Leustat
Leustatin
Leustatin (TN)
Leustatin, 2-chlorodeoxyadenosine, Cladribine
Litak
MLS000028377
MLS000028484
MLS000759397
MLS001077345
MolPort-002-054-532
MolPort-005-935-074
Movectro
Mylinax
NCGC00022567-05
NCGC00164384-01
NSC 105014
NSC 105014-F
NSC-105014
RWJ 26251
RWJ-26251
RWJ-26251-000
S1199_Selleck
SAM001246526
SMR000058553
UNII-47M74X9YT5
ZINC03798064
cladribina
cladribine
cladribinum
13
Folic Acidapproved, nutraceutical, vet_approvedPhase 3, Phase 2427959-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
14Prednisolone hemisuccinatePhase 2, Phase 3, Phase 11153
15Prednisolone phosphatePhase 2, Phase 3, Phase 11153
16Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17171
17Prednisolone acetatePhase 2, Phase 3, Phase 11153
18Anti-Infective AgentsPhase 2, Phase 3, Phase 121402
19Antineoplastic Agents, HormonalPhase 3, Phase 2, Phase 15407
20Methylprednisolone acetatePhase 2, Phase 3, Phase 11153
21Methylprednisolone HemisuccinatePhase 2, Phase 3, Phase 11153
22Peripheral Nervous System AgentsPhase 2, Phase 3, Phase 122776
23Alkylating AgentsPhase 2, Phase 3, Phase 14694
24Antineoplastic Agents, AlkylatingPhase 2, Phase 3, Phase 14474
25Immunosuppressive AgentsPhase 3, Phase 2, Phase 112770
26Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 2, Phase 112767
27HormonesPhase 3, Phase 2, Phase 113979
28Antirheumatic AgentsPhase 3, Phase 2, Phase 110627
29glucocorticoidsPhase 3, Phase 2, Phase 14920
30AntimetabolitesPhase 3, Phase 2, Phase 111774
31Anti-Inflammatory AgentsPhase 3, Phase 2, Phase 110355
32Hormone AntagonistsPhase 3, Phase 2, Phase 112778
33Antimitotic AgentsPhase 3, Phase 25498
346-MercaptopurinePhase 3, Phase 2199
35Antineoplastic Agents, PhytogenicPhase 3, Phase 25420
36AnalgesicsPhase 2, Phase 311287
37Analgesics, Non-NarcoticPhase 2, Phase 36260
38Dermatologic AgentsPhase 3, Phase 25674
39Nucleic Acid Synthesis InhibitorsPhase 3, Phase 24855
40Folic Acid AntagonistsPhase 3, Phase 22200
41Anti-Inflammatory Agents, Non-SteroidalPhase 2, Phase 34295
42Vitamin B ComplexPhase 3, Phase 24229
43Tocolytic AgentsPhase 2, Phase 3708
44gamma-GlobulinsPhase 2, Phase 3317
45Antiviral AgentsPhase 2, Phase 3, Phase 19732
46ImmunoglobulinsPhase 2, Phase 36045
47Rho(D) Immune GlobulinPhase 2, Phase 3317
48Immunoglobulins, IntravenousPhase 2, Phase 3324
492-chloro-3'-deoxyadenosinePhase 2, Phase 332
50Cyclooxygenase InhibitorsPhase 2, Phase 32778

Interventional clinical trials:

(show all 34)
idNameStatusNCT IDPhase
1H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell HistiocytosisCompletedNCT00488605Phase 3
2LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisRecruitingNCT02205762Phase 2, Phase 3
3Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)RecruitingNCT02670707Phase 3
4T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic DisordersActive, not recruitingNCT00176826Phase 2, Phase 3
5A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell HistiocytosisUnknown statusNCT01395004Phase 2
6Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic AnemiaUnknown statusNCT00008164Phase 2
7Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant DiseasesUnknown statusNCT00084695Phase 2
8Treatment of Resistant Langerhans Cell Histiocytosis With ENBRELCompletedNCT00048373Phase 2
9Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCHCompletedNCT00588536Phase 2
10Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell HistiocytosisRecruitingNCT02425904Phase 2
11Methotrexate and Cytosine in Adult Langerhans Cell HistiocytosisRecruitingNCT02389400Phase 2
12A Study of Lenalidomide for Adult Histiocyte DisordersRecruitingNCT02523040Phase 2
13CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantRecruitingNCT02061800Phase 1, Phase 2
14Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell HistiocytosisActive, not recruitingNCT01473797Phase 2
15Stem Cell Transplant for Immunologic or Histiocytic DisordersActive, not recruitingNCT00176865Phase 2
16Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell HistiocytosisTerminatedNCT00618540Phase 2
17Blood Stem Cell Transplant in Treating Patients With Hematologic CancerTerminatedNCT00008216Phase 2
18Clofarabine for Langerhans in PediWithdrawnNCT01796405Phase 2
19Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
20A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent SubjectsRecruitingNCT01677741Phase 1
21Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesActive, not recruitingNCT01471067Phase 1
22Indium In 111 Pentetreotide in Treating Patients With Refractory CancerTerminatedNCT00002947Phase 1
23Cardiovascular Risk Factors and LCH in AdultsUnknown statusNCT00483925
24Ceftriaxone in Non-neutropenic FeverUnknown statusNCT01225718
25Combination Chemotherapy in Treating Young Patients With Langerhans Cell HistiocytosisCompletedNCT00276757
26Prospective Evaluation of Adult Pulmonary Langerhans Cell HistiocytosisCompletedNCT01225601
27Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung FunctionCompletedNCT01651507
28Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766
29Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell HistiocytosisRecruitingNCT02665546
30Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy MeasurementRecruitingNCT02608619
31CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant DiseaseRecruitingNCT01966367
32Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune DeficienciesRecruitingNCT01652092
33Collecting and Storing Tissue From Young Patients With CancerRecruitingNCT00898755
34Allogeneic Bone Marrow Transplantation in Patients With Primary ImmunodeficienciesTerminatedNCT00006054

Search NIH Clinical Center for Letterer-Siwe Disease

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: histiocytosis, langerhans-cell

Genetic Tests for Letterer-Siwe Disease

About this section

Anatomical Context for Letterer-Siwe Disease

About this section

MalaCards organs/tissues related to Letterer-Siwe Disease:

36
Lymph node, Spleen, Bone, Lung, Liver, Bone marrow, Skin

Publications for Letterer-Siwe Disease

About this section

Articles related to Letterer-Siwe Disease:

(show top 50)    (show all 127)
idTitleAuthorsYear
1
Gastrointestinal: Letterer Siwe disease: An uncommon gastrointestinal presentation. (26757250)
2016
2
Letterer-Siwe disease associated with chronic myelomyonocytic leukemia: a fortuitous association? (20372775)
2010
3
Langerhans cell histiocytosis, a case of Letterer Siwe disease. (19785312)
2009
4
A case report of langerhans histiocytosis presenting sequentially over a 21-year period with Letterer-Siwe disease, hand-Schuller-Christian disease and eosinophillic granuloma of bone. (17114962)
2006
5
Splenic infarction in Letterer-Siwe disease. (15910461)
2005
6
Quiz. Langerhans cell histiocytosis (Letterer-Siwe disease). (17642901)
2003
7
Letterer siwe disease. (17664795)
2001
8
Letterer-Siwe disease with bilateral temporal bone involvement. (9006683)
1997
9
Enhanced expression of c-myc and H-ras oncogenes in Letterer-Siwe disease. A sequential study using colorimetric in situ hybridization. (2252422)
1990
10
Congenital Letterer-Siwe disease with intrauterine fetal death: a case report and review of the literature. (1982543)
1990
11
Letterer-Siwe disease in adults. (2642729)
1989
12
Letterer-Siwe disease and subacute monocytic leukemia. (2808842)
1989
13
Letterer-Siwe disease (histiocytosis-X) (a case report). (3262156)
1988
14
Letterer-Siwe disease: immunopathologic study with a new monoclonal antibody. (3259591)
1988
15
Letterer-Siwe disease: immunohistochemical evidence for a proliferative disorder involving immature cells of Langerhans lineage. (3135661)
1988
16
Precocious tooth eruption and loss in Letterer-Siwe disease. (3214622)
1988
17
Letterer-Siwe disease in an adult. (3829721)
1987
18
Histiocytosis X: overlapping form between Letterer-Siwe disease and Hand-SchA1ller-Christian disease with advanced thymic involvement and obstructive jaundice. (3497999)
1987
19
Lymphohistiocytosis in childhood. Pathologic comparison with fatal Letterer-Siwe disease (disseminated visceral histiocytosis X). (3822757)
1987
20
Skin scrapping in the diagnosis of Letterer-Siwe disease. (3679480)
1987
21
Giant cell pneumonia in Letterer-Siwe disease. (3618221)
1987
22
A child with Letterer Siwe disease. (3774344)
1986
23
Letterer-Siwe disease in the ninth decade. (3973131)
1985
24
Orbital infiltration in Letterer-Siwe disease. (6690498)
1984
25
Letterer-Siwe disease in an octogenarian. (6546937)
1984
26
Malignant histiocytosis and Letterer-Siwe disease. Neoplasms of T-zone histiocyte with S100 protein. (6687444)
1983
27
Letterer-Siwe disease with nail involvement. (6851645)
1983
28
Letterer-Siwe disease. (6679501)
1983
29
Ultrastructural study of Letterer-Siwe disease in three infants, one complicated by pneumocystosis. (6336297)
1983
30
Letterer-Siwe disease: a study of thirteen cases over a 21 - year period. (7059511)
1982
31
An ultrastructural and immunohistochemical study on mandibular lesion of Letterer-Siwe disease. (6801234)
1981
32
Congenital Letterer-Siwe disease associated with protein losing enteropathy. (7449792)
1980
33
Liver lipids in Letterer-Siwe disease. (7449795)
1980
34
Letterer-Siwe disease in an elderly patient: histological and ultrastructural findings. (535172)
1979
35
The pathology of adult type Letterer-Siwe disease. (535171)
1979
36
Letterer-Siwe disease in the adult. (535170)
1979
37
Letterer Siwe disease--report of a case. (541095)
1979
38
Letterer-Siwe disease. Presentation as an otologic problem. (672366)
1978
39
Letterer-Siwe disease with lipid-containing vacuolated cells--an autopsy case. (735815)
1978
40
A 9-year observation of Letterer-Siwe disease in a child with long-term maintenance of remission. (685680)
1978
41
Posterior choroidal involvement in Letterer-Siwe disease. (739337)
1978
42
Letterer-Siwe disease: report of case. (330581)
1977
43
Letterer-Siwe disease: a caring case study. (271915)
1977
44
A Chinese girl with features of Letterer-Siwe disease, histiocytic medullary reticulosis and monocytic leukaemia. (270819)
1977
45
Histiocytosis X: late manifestations in a long-term survivor of Letterer-Siwe disease. (1086897)
1976
46
Systemic giant-cell histiocytosis: report of a case and a review of the adult form of Letterer-Siwe disease. (793710)
1976
47
Letter: Hypofibrinogenemia in Letterer-Siwe disease and in familial hemophagocytic reticulosis. (1151539)
1975
48
Letterer-Siwe disease. (4438301)
1974
49
Congenital Letterer-Siwe disease. (4838016)
1974
50
Ocular involvement in Letterer-Siwe disease. (4697182)
1973

Variations for Letterer-Siwe Disease

About this section

Expression for genes affiliated with Letterer-Siwe Disease

About this section
Search GEO for disease gene expression data for Letterer-Siwe Disease.

Pathways for genes affiliated with Letterer-Siwe Disease

About this section

GO Terms for genes affiliated with Letterer-Siwe Disease

About this section

Cellular components related to Letterer-Siwe Disease according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extracellular regionGO:00055768.7AVP, CD163, F13A1, LIF, LYZ, S100B
2extracellular spaceGO:00056158.0AVP, CD40, CSF1, LIF, LYZ, S100B

Biological processes related to Letterer-Siwe Disease according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1astrocyte differentiationGO:004870810.3LIF, S100B
2face developmentGO:006032410.2BRAF, MAP2K1
3ERK1 and ERK2 cascadeGO:007037110.2AVP, MAP2K1
4positive regulation of axonogenesisGO:005077210.2BRAF, MAP2K1
5positive regulation of macrophage differentiationGO:004565110.1CSF1, LIF
6regulation of axon regenerationGO:00486799.9BRAF, MAP2K1
7positive regulation of tyrosine phosphorylation of Stat1 proteinGO:00425119.9CD40, LIF
8thyroid gland developmentGO:00308789.5BRAF, MAP2K1
9positive regulation of cell proliferationGO:00082849.4AVP, CSF1, LIF, S100B
10positive regulation of peptidyl-serine phosphorylationGO:00331389.2AVP, BRAF, LIF
11positive regulation of gene expressionGO:00106288.6AVP, BRAF, CSF1, LIF, MAP2K1

Sources for Letterer-Siwe Disease

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet